Dear Doctor

The patient carrying this letter to you would like your support in a highly effective treatment for alcoholism: it is called TSM and has a 78% cure rate. It requires a prescription for naltrexone.

The FDA approved naltrexone in 1995 for use in the treatment of alcohol dependence. Important new evidence has been obtained since then about how to use naltrexone much more effectively.

First, a dual double-blind clinical trial\(^1\) showed that the usual protocol of having patients take naltrexone while abstinent is not effective. To be effective, naltrexone and alcohol must be in the system concurrently. Therefore, naltrexone must always be taken one hour before consuming alcohol. The resulting mechanism of extinction then gradually reduces craving and drinking over several months, and produces a natural detoxification - thus avoiding the distress and complications of rapid withdrawal. The result has been replicated and is consistent with findings from nearly all of the 82 clinical trials conducted to date.\(^2\)

Second, it is now clear that naltrexone can be prescribed by doctors without an accompanying program of intensive counselling. Naltrexone was originally approved by the FDA as an adjunct within comprehensive programs of alcoholism treatment. The results of Project Combine (\textit{JAMA}. 2006), the largest clinical trial in the alcohol field, showed, however, that naltrexone was effective without the need for intensive counselling where patients are treated in general medical settings.\(^3\)

The bottom line is that TSM has proven to be far more successful than any other treatment for alcoholism on the market to date, and your patient is keen to try this method.

Detailed information can be found in Dr. Roy Eskapa’s book, \textit{The Cure for Alcoholism}\(^4\) containing instructions to physicians, can be downloaded on the internet at: www.TheCureForAlcoholism.com - Click on ‘About the Book’ Chapter 17 – ‘For Medical Professionals’

Additional documentation may be requested by emailing: TSMtreatment@gmail.com

David Sinclair, Ph.D.
National Institute for Health and Welfare (THL)
Helsinki, Finland

Stephen Cox, MD
Head of the National Anxiety Association
University of Kentucky, Lexington, KY
Information for Prescribing Naltrexone


